View Clinical Trial (Medical Research Study)

Evaluation of Pascal Laser Trabeculoplaty - NCT00838721-95128(Clinical Trial 269651)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  San Jose
State:  
CA
Zip Code: 95128
Conditions: Open Angle Glaucoma - Ocular Hypertension
Purpose: Laser Trabeculoplasty has been shown to be effective in lowering intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG). Although initially demonstrated with the Argon laser (ALT), several other laser systems have also been employed with comparable efficacy. Recently, Selective Laser Trabeculoplasty (SLT) has been shown to lower intraocular pressure comparable to ALT. The advantage of SLT is that the target eye structure, the trabecular meshwork, remains intact with minimal damage at the cellular level. In contrast, ALT lowers IOP at the expense of scarring of the trabecular meshwork. The purpose of this study is to evaluate the efficacy of lowering IOP with Pascal Laser Trabeculoplasty (PLT) employing reduced energy levels compared to ALT and a computer guided pattern of laser treatment applications.
Study summary:
Criteria: Inclusion Criteria: 1. Otherwise healthy males and females, older than 18 years of age with two (2) sighted eyes 2. Have OAG, PXG, or combined mechanism glaucoma - as long as their angles are open 3. Have uncontrolled IOP (>24mmHg); or controlled with Medicine(s) 4. If on medical treatment, have undergone a washout period of at least one month prior to Pascal treatment 5. Able and willing to comply with the treatment/follow-up schedule and requirements; 6. Able to provide written informed consent Exclusion Criteria: 1. Pregnant, intending to become pregnant during course of study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding 2. Have an advanced visual field defect within 10° of fixation 3. Have had previous glaucoma surgery, except for peripheral iridotomy 4. Have corneal disease obviating the use of corneal applanation for a reliable IOP measurement, or would cause difficulty in viewing the TM by means of gonioscopic lens 5. Using systemic steroids 6. Participation in a study of another device or drug within 3 month prior to study enrollment or during this study, and as per the Investigator's careful discretion, as long as not contradictory to any of the above criteria 7. Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study 8. No concomitant use of IOP lowering medicine (Group 1) 9. No co-existing ocular pathology with the exception of Cataract.
Study is available at: Santa Clara Valley Medical Center
San Jose, CA 95128
United States

Primary Contact:
Kevin Hutchcroft
Email: kevin.hutchcroft@hhs.sccgov.org
Phone: 408-885-3856

Secondary Contact:
Christopher J Engelman, MD
Email: engelman@stanford.edu
Phone: 408-885-6877
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.